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Abstract
Background: Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly
effective for the treatment of metastatic colorectal cancer. However, in light of safety and efficacy concerns, the best
combination regimen for first-line therapy still needs to be defined. The current study reports on the bimonthly FOLFIRI
protocol consisting of irinotecan with continuous FA/5-FU in five German outpatient clinics, with emphasis on the safety and
efficiency, quality of life, management of delayed diarrhea, and secondary resection of regressive liver metastases.
Methods: A total of 35 patients were treated for metastatic colorectal cancer. All patients received first-line treatment
according to the FOLFIRI regimen, consisting of irinotecan (180 mg/m2), L-FA (200 mg/m2) and 5-FU bolus (400 mg/m2) on day
1, followed by a 46-h continuous infusion 5-FU (2400 mg/m2). One cycle contained three fortnightly administrations. Staging was
performed after 2 cycles. Dosage was reduced at any time if toxicity NCI CTC grade III/IV was observed. Chemotherapy was
administered only to diarrhea-free patients.
Results: The FOLFIRI regimen was generally well tolerated. It was postponed for one-week in 51 of 415 applications (12.3%).
Dose reduction was necessary in ten patients. Grade III/IV toxicity was rare, with diarrhea (14%), nausea/vomiting (12%),
leucopenia (3%), neutropenia (9%) and mucositis (3%). The overall response rate was 31% (4 CR and 7 PR), with disease control
in 74%. After primary chemotherapy, resection of liver metastases was achieved in three patients. In one patient, the CR was
confirmed pathologically. Median progression-free and overall survival were seven and 17 months, respectively.
Conclusions: The FOLFIRI regimen proved to be safe and efficient. Outpatient treatment was well tolerated. Since downstaging
was possible, combinations of irinotecan and continuous FA/5-FU should further be investigated in neoadjuvant protocols.
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Background
Patients with advanced ColoRectal  Cancer (CRC) have
been demonstrated to benefit from chemotherapeutic
treatment in terms of both quality and duration of life [1].
Of these treatments, fluoropyrimidines are the most often
used and best investigated drugs [2,3]. 5-Fluorouracil (5-
FU)-based chemotherapy, – usually biomodulated with
folinic acid (FA) to increase its affinity for thymidylate
synthase [4] -, was associated with an approximate dou-
bling of the median survival compared to routine stand-
ard of care [5]. Additionally, recent phase III studies
suggested that combinations of FA/5-FU with irinotecan
or oxaliplatin resulted in improved response rates and
prolonged survival [6-9]. These encouraging results
prompted the use of combination therapy of irinotecan
and FA/5-FU as a first line chemotherapy in CRC.
Irinotecan (CPT-11), a potent inhibitor of the enzyme
topoisomerase I, has demonstrated anti-tumorogenic
activity in metastatic colorectal cancer, when used alone
or in combinations with FA/5-FU, as adjuvant or pallia-
tive treatment (for review see 10 or 11). In randomized
phase III clinical trials, second-line therapy with irinote-
can significantly improved survival compared to support-
ive care [12] or to infusional FA/5-FU [13]. In the first-line
setting of metastatic colorectal cancer, two randomized
multi-center phase III clinical trials demonstrated syner-
gistic activity of irinotecan with both bolus and infusional
FA/5-FU regimens [6,7]. In both studies, combinations of
irinotecan and FA/5-FU were superior to the control arms,
irinotecan alone or FA/5-FU, specifically in regard to
response rate, progression-free, and overall survival.
However, the best regimen of irinotecan and FA/5-FU has
yet to be defined. Altogether, irinotecan combined with
continuous FA/5-FU infusions seemed to be superiorly
active and less toxic than combination with FA/5-FU
bolus regimens [6,7]. Recently, irinotecan was investi-
gated in a bi-monthly protocol with bolus FA/5-FU and a
continuous 48 h infusion 5-FU (simplified LV5-FU2 regi-
men; FOLFIRI) [14-16]. In a consecutive phase III clinical
trial, a response rate of 56% was achieved with FOLFIRI,
as compared to 39% achieved with the original Saltz pro-
tocol [6,14].
Furthermore, irinotecan schedules of weekly and of once
every two or three weeks demonstrated similar efficacy
and quality of life, as well as significantly lower incidences
of severe diarrhea in patients with 5-FU-refractory, meta-
static colorectal cancer [15-17]. In contrast to the irinote-
can and bolus FA/5-FU regimen, which has attracted
criticism due to unexpectedly high early death rates due to
gastrointestinal toxicity and thromboembolic events
observed in two subsequent trials [18,19], no increased
60-day mortality rate was found in two recent trials, each
with continuous 5-FU treatment arms [14,17,20,21].
To date, little data is available regarding irinotecan com-
bined with the simplified bi-monthly LV5-FU2 regimen as
a first-line treatment in patients with metastatic colorectal
cancer [14]. Therefore, we initiated this prospective open-
label, multi-center phase IV clinical trial to evaluate its
toxicity and efficacy in German outpatient clinics. We
were especially interested in the safety of this regimen in
an outpatient setting, with particular emphasis placed on
the prompt and aggressive management of delayed
diarrhea with loperamide, hospitalization and parenteral
rehydration in case of refractory diarrhea lasting more
than 48 hours [22,23]. Furthermore, all patients were
closely monitored for the possibility of resection of liver
metastases after successful response.
Methods
Accrual and eligibility
After approval by the local ethical committee, patients
were consecutively recruited from five German outpatient
clinics (one university hospital, one community hospital,
and three general practices). Eligibility requirements
included (1) histologically documented adenocarcinoma
of the colon or rectum and progressive measurable meta-
static disease, (2) minimum life expectancy of three
months, (3) Karnofsky performance status ≥ 60, (4) ade-
quate hematologic, hepatic, and renal function, and (4)
no prior chemotherapy for metastatic disease. Participants
needed to be between 18 and 75 years of age. This study
required that previous adjuvant 5-FU-based therapy with
or without radiation therapy be completed at least 6
months prior to entry. Patients with CNS metastases,
bowel obstruction, or ileus were excluded from the study.
The study was approved by the ethics commission board
responsible for all participating institutions. Prior to treat-
ment, all patients gave written informed consent.
Treatment and management of toxicity
As previously described [14-16], treatment consisted of
the bi-monthly combination of irinotecan 180 mg/qm
given as a 90-min intravenous infusion, day (d)1, FA 200
mg/m2 d1, 5-FU bolus 400 mg/m2 d1, followed by 5-FU
46 h continuous infusion 2400 mg/m2 (simplified LV5-
FU2 schedule). To prevent expected toxicities, patients
were carefully informed of the potential risk of delayed
diarrhea and neutropenia and the need for early interven-
tion with loperamide [22] and metoclopramide, prophy-
lactic antibiotics, or hospitalization and parenteral
rehydration in case of refractory diarrhea lasting more
than 48 hours. Patients with loperamide-resistant
diarrhea defined as loose stools persisting for more than
24 hours despite adequate treatment with loperamide
would receive a trial of the oral steroid budesonide (9 mgBMC Cancer 2004, 4:38 http://www.biomedcentral.com/1471-2407/4/38
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per day for a maximum of 4 days) [23]. Atropine was
given for irinotecan-related cholinergic symptoms if
needed [25]. Antiemetic treatment was performed using
metoclopramide or HT5 antagonists in a sequential
manor. The prophylactic use of colony-stimulating factors
was not permitted. Treatment was continued until one of
the following occurred: disease progression, unacceptable
adverse effects, or withdrawal of consent by the patient.
Assessments
Primary measures of the study were the overall objective
response rate (ORR, complete and partial responses),
overall survival, and quality of life. Secondary measures
included the disease control rate (ORR + stable disease),
time to progression, and frequency and severity of toxici-
ties. Quality of life was assessed after inclusion into the
study and as often as possible during the course of treat-
ment, using the EORTC QLQ-C30 (version 2) question-
naire [24].
Safety assessments and complete blood counts were per-
formed weekly. Toxicity was graded according to National
Cancer Institute Common Toxicity Criteria (NCI CTC).
Toxicities not defined by NCI CTC criteria were classified
as grade 0 (none), grade I (minor), grade II (moderate),
grade III (severe), and grade IV (life-threatening). In case
of any toxicity grade II, with the exception of hand-foot
syndrome or alopecia, the next scheduled doses of irinote-
can, folinic acid and 5-FU were delayed for a maximum of
1 week (or resolution of diarrhea for at least five days). In
case of toxicity grade III/IV or if improvement from grade
II to I (or resolution of diarrhea) was not achieved by two
weeks, the following chemotherapy doses were reduced
by 20 percent. If grade III/IV toxicity did not improve by 2
weeks, treatment was discontinued. Dose reductions were
mandatory from the first cycle of chemotherapy in case of
toxicity higher than grade II, and chemotherapy was
resumed only after complete recovery from diarrhea.
Tumor response was assessed according to World Health
Organization (WHO) criteria. Tumor reassessment by the
same imaging method used to establish baseline tumor
measurement was generally performed after every two
courses of therapy until progression. A complete response
(CR) was defined as complete disappearance of evidence
of cancer. A partial response (PR) was defined as a reduc-
tion in the sum of the products of the bi-perpendicular
diameters of all measurable lesions by at least 50%. Pro-
gressive disease (PD) was defined as an increase in the
sum of the products of the greatest bi-perpendicular diam-
eters of all measurable lesions by at least 25% or the
appearance of new lesions. Stable disease was defined as
any reduction or increase in measurable lesions which did
not meet the criteria for PR or PD. Confirmed objective
responses were those for which a follow-up scan obtained
at least four weeks later demonstrated the persistence of
the response. The assessment of response and progression
was based on investigator-reported measurements.
Statistical analysis
Statistical analysis including survival analysis according to
Kaplan-Meier was performed with the SPSS software pack-
age. The deadline for data evaluation was March 15, 2004.
Survival was measured from the time of diagnosis to the
date of death or last follow-up. Progression-free survival
was calculated from treatment onset to the time of pro-
gression, study withdrawal or death of any cause. Patients
who received at least one dose of the treatment regimen
were evaluated for toxicity, and patients who completed at
least two chemotherapy cycles were evaluated for
response.
Results
Between 10/2001 and 5/2003, 35 consecutive patients
(25 male, 10 female) with metastatic colorectal cancer
were enrolled into the study. The median age of these
patients was 62 years, ranging from 38 to 73. Baseline
characteristics of all patients are summarized in table 1.
Most patients were in good overall physical condition,
although 60% had at least two metastatic sites. All
patients had undergone surgery prior to chemotherapeu-
tic treatment. Six patients previously had received
Table 1: Patient characteristics of all 35 patients with respect to 
primary tumor side, metastatic sites, number of metastatic sites 
and previous treatment as well as gender and age.
Characteristics No.
No. Patients 35
Gender, male/female 25/10
median age, years (range) 62 (38–75)
Primary tumor site
Colon 21
Rectum 12
Ileum 1
Metastatic sites
Liver 26
Lung 12
Lymph nodes 6
Local relapse 3
other sites 3
Peritoneum 8
No. of metastatic sites
1 14
2 17
≥3 4
Previous treatment
surgery only 28
surgery+radiotherapy+adjuvant chemotherapy 1
surgery+adjuvant chemotherapy 5BMC Cancer 2004, 4:38 http://www.biomedcentral.com/1471-2407/4/38
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adjuvant chemotherapy, one of them in combination
with radiation therapy. All patients were evaluated for tox-
icity, for response, and survival.
The 35 patients received a total of 151 chemotherapy
cycles (mean 4,3 per patient), consisting of 451 adminis-
trations. Overall, 51 (12,3 %) of all administrations had
to be delayed for one week. During the complete study
period, 19 patients had a delay of therapy for a median of
nine days and in 10 patients (29%) a dose reduction was
necessary at some point during the treatment period. The
most common cause for discontinuation of study treat-
ment was disease progression (18 patients, 51%). In case
of discontinuation, 16 (46%) patients received a second
line treatment with either oxaliplatin plus a FA/5-FU con-
sisting regimen or an epidermal growth factor receptor
antagonist.
Hematologic toxicity was mild to moderate in the major-
ity of patients (table 2). Only one patient (3 %) had a
grade III/IV leucopenia, three patients (9 %) had a grade
III neutropenia, and grade III or IV anemia or thrombocy-
topenia were not observed. The predominant non-hema-
tologic toxicities were nausea/vomiting and delayed
diarrhea, which affected a total of 21 (60%) and 10 (29%)
patients, respectively. However, grade III/IV of these side
effects were only observed in 4 (11%) and 2 (6%)
patients, respectively (table 3). Other non-hematological
toxicities were predominantly mild, including mucositis
(I°, 5 patients, 14%), fever (I°/II°, 5 patients, 14%),
cholinergic syndrome (I°, 2 patients, 6%), constipation
(I°, 8 patients, 23%), alopecia (I°, 9 patients, 26%, II°, 1
patient, 3%), asthenia (I°, 2 patients, 6%). Regarding the
irinotecan induced delayed diarrhea, 11 patients received
at least one course of loperamide [22] and 1 patient
received budesonide for loperamide refractory diarrhea
[23]. In two patients treatment-related hospital admis-
sions as a result of III/IV leucopoenia and grade III
diarrhea were required. Other adverse events in three
patients included a bowel obstruction due to local recur-
rence, unexplained vertigo, and renal failure due to ure-
thral obstruction. Pulmonary embolism did not occur in
any patients during treatment.
With regard to response, four complete (CR) and seven
partial responses were seen, and thus an overall response
rate of 31% was observed (table 4). In addition, 15
patients (43%) had stable disease (disease control rate,
74%). Disease progression occurred in nine patients
(26%). Resectability of metastases was achieved in three
patients. In one patient CR, was pathologically confirmed.
Median progression-free survival was seven months and
overall survival was 17 months (95% confidence intervall:
9–25 months, figure 1).
Quality of life data were obtained before and at least once
during treatment from 13 patients [24]. The 13 patients
evaluated for quality of life did not differ in their pattern
of response to chemotherapy from the total population of
all evaluated patients. Global health status improved
slightly during treatment compared to pre-therapy values
(figure 2). In addition, patients treated with the FOLFIRI
regimen had a small increase in emotional and physical
wellbeing compared to a previously reported cohort of
untreated patients. No remarkable changes in the other
items of the questionaire were seen during treatment,
especially with regard to therapy-dependent symptoms
such as nausea and vomiting, diarrhea and pain. Slightly
increased nausea and fatigue were observed in our
Table 2: Hematologic toxicity. Number of patients affected with 
each side effect are listed in the corresponding rows.
N C I  C T C  G r a d e 1234
Leukopenia 7101
Neutropenia 4730
Anaemia 3100
Table 3: Non-hematologic toxicities. Number of patients affected 
with each side effect are listed in the corresponding rows.
NCI CTC Grade 1 2 3 4
Nausea/Vomiting 9840
Acute diarrhea 3021
Delayed diarrhea 4411
Cholinergic syndrome 2000
Fever 3200
Mucositis 5010
Obstipation 8000
Asthenia 2000
Alopezie 9100
Table 4: Summary of the response of 35 evaluated patients, 
divided into CR, PR, SD and PD.
Response No.(%)
Complete Response 4 (11)
Partial Response 7 (20)
Overall Response Rate (CR+PR) 11 (31)
Stable disease 15 (43)
Tumor control rate (CR+PR+SD) 26 (74)
Progressive disease 9 (26)BMC Cancer 2004, 4:38 http://www.biomedcentral.com/1471-2407/4/38
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patients. However, a clear trend could not be concluded
from our data.
Discussion
In the current phase IV study we evaluated toxicity and
efficacy of the FOLFIRI combination of irinotecan with
FA/5-FU as first-line chemotherapy for metastatic colorec-
tal cancer. This combination was established within a
phase I clinical trial with a recommended irinotecan dose
of 180 mg/qm [15,16]. Irinotecan-containing regimens
have been the most commonly used chemotherapy proto-
cols for metastatic colorectal cancer in North America
since the publications of Saltz et al. [3,6,7,12,17]. After
unexpectedly high early death rates, due to gastrointesti-
nal toxicity and thromboembolic events, which were
reported in two subsequent trials due to gastrointestinal
toxicity and thromboembolic events, the safety of the
Saltz regimen became a subject of considerable debate
[18,19]. However, in our previous experience with this
regimen we did not observe any major complications
[25]. Moreover, additional comprehensive data showed
that combinations of irinotecan with continuous FA/5-
FU, either weekly or bi-monthly, resulted in higher
response rates and better survival. Therefore, we investi-
gated the bi-monthly FOLFIRI schedule in an outpatient
setting for its safety and clinical efficacy.
In the majority of our patients the FOLFIRI regimen was
well tolerated. Gastrointestinal toxicity or thrombembolic
events were never fatal. Most hospitalizations were for
prevention rather than treatment of life-threatening con-
ditions. Delayed diarrhea, a well known side effect of iri-
notecan [22], was generally managed in the outpatient
setting using loperamide, which was administered to
approximately one third of the patients. Budesonide,
which has demonstrated activity in loperamide-refractory
diarrhea was required in only one of our patients (3%).
Overall, we observed relatively low toxicity in our study,
with NCI CTC grade III leucopenia amounting to 3%,
diarrhea to 14% and nausea/vomiting to 11%. The toxic-
ity observed in our study was lower than that reported by
Douillard et al. in the pivotal European first-line trial in
the patient group receiving weekly irinotecan (80 mg/
qm), 24-h HD-5-FU (2300 mg/qm) preceded by 2-h FA
500 mg/qm [7]. In this patient group, grade III/IV toxici-
ties were reported for leucopenia 20.4%, diarrhea 44.4%
and nausea 7.4%. The lower toxicity in our study might be
due to the lower per day doses of 5-FU (2400 mg/qm
administered over 48 h) and L-FA (200 mg/qm) used. In
the EORTC phase III study 40986, comparing first-line
AIO schedule alone with irinotecan (80 mg/qm), FA 500
mg/qm and continuous FA/5-FU (2300 mg/qm), the 5-
FU-dose had to be reduced to 2000 mg/qm because of ini-
tially high toxicity in an interim analysis [26]. In addition,
lower toxicity in our study may have been more limited
because of the early and rigorous dose reductions
according to our protocol. Furthermore, we observed
improved physical and emotional status and an increase
in global health status during treatment [24]. This is in
concordance with our previously reported data [25].
Tournigand et al. demonstrated an increase in weight of at
least 5% in 35% and an improved physical status in 35%
of the irinotecan/FA/5-FU treated patients, respectively
[14]. Koehne et al. reported a significantly better quality of
life in the irinotecan/FA/5-FU group compared to FA/5-
FU [26].
The response rate achieved in our study (31%) was quite
comperable tp previously published data [6,7,14,26]. In
these studies, response rates were 40–56 % with time to
progression (TTP) of 6–8 months. Tumor control
(CR+PR+SD) was achieved in 74% of our patients, which
is similar to other reports. Median progression-free and
overall survival, was comparable, but slighty less than 8,5
and 21,5 months reported by Tournigand [14].
Three reasons may account for these differences in sur-
vival between the studies. The most important reason may
Overall survival Figure 1
Overall survival. The time to progression (TTP) and overall 
survival (OS, in months) are plotted as Kaplan-Meier-curves. 
Overall survival is drawn as a continuous line, total progres-
sion free survival as a dotted curve. TTP and OS were 7 and 
17 months, respectively.
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Quality of life assessed by the QLQ-C30 questionnaire Figure 2
Quality of life assessed by the QLQ-C30 questionnaire. Quality of life was assessed immediately after inclusion into the study 
and at least once during the course of treatment, using the standardized EORTC QLQ-C30 questionnaire, version 2. Overall 
scores range from 0 to 100, divided into several subsets such as physical ability, emotional feelings, nausea/vomiting, fatigue, 
pain or diarrhea. Higher scores on global health status and physical functioning and lower scores on symptom scales and emo-
tional assessment indicate a better quality of life.
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be that a higher percentage of patients (21 patients, 60%
compared to 41% and 10% reported by Tournigand and
Saltz, respectively) in our study had two or more meta-
static sites, indicating a larger tumor burden and conse-
quently a worse prognosis regarding survival [6,14].
Second, our study included patients with carcinoma of the
rectum (12 patients, 34% versus 15 %). And finally, as
much as five (14%) of our patients had previously
received adjuvant FA/5-FU-containing chemotherapy or
radiotherapy compared with 10% of the patients in the
other study [6].
It appears particularly noteworthy that after chemother-
apy three of our patients achieved surgical resectability of
their metastases. To our knowledge these results are the
first ever reported to suggest a potential role for the FOLF-
IRI regimen in the neoadjuvant setting. Thus far, studies of
regional chemotherapy for initially unresectable colorec-
tal liver metastases could demonstrate some success with
secondary curative surgery. In two recently published ret-
rospective studies chronomodulated chemotherapy with
oxaliplatin and FA/5-FU was used as neoadjuvant treat-
ment for patients with unresectable colorectal liver metas-
tases [27,28]. Therefore, combination regimens of
irinotecan or oxaliplatin with FA/5-FU should be strongly
considered as standard first-line chemotherapy for meta-
static colorectal cancer. Through multidisciplinary efforts
involving both surgeons and medical oncologists, it
should be possible, to translate the antitumour activity of
the new first-line regimens into long-term survival benefit
for patients with initially unresectable colorectal liver
metastases.
Conclusions
The FOLFIRI regimen, consisting of irinotecan with con-
tinuous FA/5-FU over 48 h, given on an outpatient basis
was safe and well tolerated in our study. The rate of severe
side effects was comparably low with this bi-monthly reg-
imen. As tumor control was achieved in about 75% and
downstaging of metastatic disease was possible in some
cases, combinations of irinotecan plus continuous FA/5-
FU should be further investigated in neoadjuvant proto-
cols for initially unresectable liver metastases.
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FOLFIRI chemotherapeutic regimen consisting of irinote-
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